NEW
YORK, Sept. 1, 2022 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology company
focused on the treatment of primary and metastatic cancers of the
liver, will participate at the H.C. Wainwright 24th
Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 12 at 8:30 AM
ET.
A webcast of the presentation will be available at
https://journey.ct.events/view/73738b66-ee17-43a2-b94a-00d7d3908fbb.
A replay of the presentation will be available following the
event.
Management is scheduled to host one-on-one meetings throughout
the event. Investors interested in arranging one-on-one meetings
should contact your conference representative. You may also call or
email Ben Shamsian of Lytham
Partners at 646-829-9701, or shamsian@lythampartners.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the
PHP system is being developed under the tradename
HEPZATO® KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of patients with unresectable hepatic-dominant metastatic ocular
melanoma (mOM), also known as metastatic uveal melanoma (mUM) and
is considered a combination drug and device product regulated by
the United States Food and Drug Administration (FDA).
In Europe, the PHP system is
now regulated as a Class lll medical device and is approved for
sale under the trade name CHEMOSAT Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used at major medical
centers to treat a wide range of cancers of the liver.
Investor Relations Contact:
Ben Shamsian
Lytham
Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-hc-wainwright-24th-annual-global-investor-conference-on-september-12-and-13-2022-301616749.html
SOURCE Delcath Systems, Inc.